Kala Pharmaceuticals Ebitda Over Time
| KALA Stock | USD 6.65 0.16 2.47% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Kala Pharmaceuticals Performance and Kala Pharmaceuticals Correlation. Kala |
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Kala Pharmaceuticals. If investors know Kala will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Kala Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (11.67) | Quarterly Revenue Growth (1.00) | Return On Assets (0.40) | Return On Equity (2.48) |
The market value of Kala Pharmaceuticals is measured differently than its book value, which is the value of Kala that is recorded on the company's balance sheet. Investors also form their own opinion of Kala Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Kala Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Kala Pharmaceuticals' market value can be influenced by many factors that don't directly affect Kala Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Kala Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Kala Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Kala Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Ebitda Analysis
Compare Kala Pharmaceuticals and related stocks such as Mallinckrodt Plc, Lifecore Biomedical, and Lucy Scientific Discovery Ebitda Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| LFCR | (6.6 M) | 21.5 M | 33.1 M | 30.4 M | 21.9 M | 15.5 M | 15.2 M | 16.7 M | 7.2 M | (12.6 M) | 13 M | (68 M) | 2 M | 35.6 M | 37.4 M |
| SHPH | (711.2 K) | (711.2 K) | (711.2 K) | (711.2 K) | (711.2 K) | (711.2 K) | (711.2 K) | (711.2 K) | (711.2 K) | (711.2 K) | (711.2 K) | (1 M) | (4.3 M) | (5.9 M) | (5.6 M) |
| DERM | (31.6 M) | (31.6 M) | (31.6 M) | (31.6 M) | (31.6 M) | (78.8 M) | (87.4 M) | (294.8 M) | (205.5 M) | 6.5 M | 9.4 M | (32.8 M) | (23.2 M) | 1.9 M | 2 M |
| AKAN | (702 K) | (702 K) | (702 K) | (702 K) | (702 K) | (702 K) | (702 K) | (702 K) | (702 K) | (702 K) | (1.4 M) | (2.2 M) | (4.5 M) | (27.7 M) | (26.3 M) |
| ORGO | (208.7 K) | (208.7 K) | (208.7 K) | (208.7 K) | (208.7 K) | (208.7 K) | (208.7 K) | (4.6 M) | (40.9 M) | (20 M) | 37.2 M | 87 M | 40.3 M | 36 M | 18.5 M |
| BFRI | (8.8 M) | (8.8 M) | (8.8 M) | (8.8 M) | (8.8 M) | (8.8 M) | (8.8 M) | (8.8 M) | (8.8 M) | (8.8 M) | (7.5 M) | (36.8 M) | 934 K | (18.5 M) | (19.4 M) |
| CPHI | (971 K) | 23.2 M | 8 M | (13.3 M) | (34.8 M) | (10.6 M) | (1.1 M) | (1.2 M) | (709.6 K) | (433.3 K) | 106.9 K | 230.3 K | (837.7 K) | 8.4 K | 8 K |
| ALKS | (7.4 M) | 6.9 M | 173.8 M | 66.4 M | (29.2 M) | (163.3 M) | (146.4 M) | (90.8 M) | (26.8 M) | (106.9 M) | (6 M) | 176.4 M | 59.8 M | 519.5 M | 545.5 M |
| NBIX | 500 K | 30.4 M | (2.1 M) | (53.2 M) | (68.3 M) | (99.5 M) | (153.6 M) | (131.4 M) | 40.9 M | 226.6 M | 336.1 M | 218.7 M | 264.6 M | 358 M | 375.9 M |
| ITCI | (16.3 M) | (16.3 M) | (16.3 M) | (26.2 M) | (30.7 M) | (105.7 M) | (115.3 M) | (98.8 M) | (161.9 M) | (153.5 M) | (230.7 M) | (285.2 M) | (263 M) | (158.9 M) | (166.8 M) |
| DVAX | (11.7 M) | (46.8 M) | (67.6 M) | (65.2 M) | (90.7 M) | (104.6 M) | (108.5 M) | (89.2 M) | (149.6 M) | (114.8 M) | (46.8 M) | 95.7 M | 307.7 M | 9.7 M | 10.1 M |
Kala Pharmaceuticals and related stocks such as Mallinckrodt Plc, Lifecore Biomedical, and Lucy Scientific Discovery Ebitda description
My Equities
My Current Equities and Potential Positions
| Kala Pharmaceuticals | KALA |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | Massachusetts; U.S.A |
| Exchange | NASDAQ Exchange |
USD 6.65
Check out Kala Pharmaceuticals Performance and Kala Pharmaceuticals Correlation. For information on how to trade Kala Stock refer to our How to Trade Kala Stock guide.You can also try the Share Portfolio module to track or share privately all of your investments from the convenience of any device.
Kala Pharmaceuticals technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.